Twenty-Four-Month OCTA Assessment in Diabetic Patients Undergoing Fixed-Interval Intravitreal Aflibercept Therapy

Copyright 2020, SLACK Incorporated.

Détails bibliographiques
Publié dans:Ophthalmic surgery, lasers & imaging retina. - 2013. - 51(2020), 8 vom: 01. Aug., Seite 448-455
Auteur principal: Statler, Brittney (Auteur)
Autres auteurs: Conti, Thais F, Conti, Felipe F, Silva, Fabiana Q, Rachitskaya, Aleksandra, Yuan, Alex, Schachat, Andrew, Kaiser, Peter K, Singh, Rishi P, Babiuch, Amy
Format: Article en ligne
Langue:English
Publié: 2020
Accès à la collection:Ophthalmic surgery, lasers & imaging retina
Sujets:Journal Article Research Support, Non-U.S. Gov't Angiogenesis Inhibitors Recombinant Fusion Proteins Vascular Endothelial Growth Factor A aflibercept 15C2VL427D Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1